AMPD2

Across TCGA pan-cancer cohorts, AMPD2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AMPD2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AMPD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AMPD2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where AMPD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.250	0.934	.024	10	view →
CCRCC	DFS	Median	All	0.620	0.847	.004	8	view →
LSCC	DFS	Median	II,III,IV	0.835	0.989	.020	4	view →
LUAD	DFS	Quartile	All	0.778	0.383	.036	2	view →
HNSC	DFS	Median	III,IV	0.913	0.988	.033	2	view →
UCEC	DFS	Median	II,III,IV	0.826	1.000	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AMPD2–PDAC (DFS)

Open the PDAC breakdown →